Sanofi Claims IP Life Extension Needed For Double Patenting

By Editorial Team

French drugmaker Sanofi and its allies have argued before the U.S. Patent and Trademark Office Director John Squires that a Sanofi patent application should not be rejected for obviousness-type double patenting as it does not improperly extend patent life.

The Patent Trial and Appeal Board supported Sanofi's position, highlighting the importance of the case in the realm of intellectual property law.

Sanofi's legal representatives, along with other stakeholders, have submitted briefs to support their claim, emphasizing the significance of protecting intellectual property rights in the pharmaceutical industry.

This development underscores the ongoing legal battles and complexities surrounding patent applications and extensions, especially in the life sciences sector.

Key Points:

• Sanofi defends patent application against rejection for double patenting.
• Stakeholders emphasize the importance of protecting intellectual property rights.
• Legal representatives submit briefs to support Sanofi's claim.
• Case highlights complexities in patent applications and extensions in the life sciences industry.